Analysts Issue Forecasts for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Wednesday, March 19th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

STOK has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $8.33 on Thursday. Stoke Therapeutics has a fifty-two week low of $5.80 and a fifty-two week high of $17.58. The firm has a 50-day simple moving average of $9.49 and a 200-day simple moving average of $11.49. The company has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insiders Place Their Bets

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently modified their holdings of the company. RTW Investments LP increased its stake in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after purchasing an additional 471,240 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after buying an additional 265,395 shares in the last quarter. Toronto Dominion Bank acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth $35,001,000. State Street Corp boosted its position in shares of Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after acquiring an additional 38,446 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.